Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a Healthcare company (Biotechnology) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Sarepta Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.77, Sarepta Therapeutics, Inc. trades at 164.0x trailing earnings, 0.8x sales and 1.0x book value, with an EV/EBITDA of 13.9. Over the last twelve months it generated about $2.0B of revenue and $10M of net income. It runs a gross margin of 56.2%, an operating margin of -2.5% and a net margin of 0.8%. It shows return on equity of 1.0%, return on invested capital of -0.7% and a free cash flow yield of -2.0%. On the balance sheet: a debt-to-equity ratio of 0.69 and a current ratio of 3.46. Over the past 52 weeks the share price ranged from $14.58 to $24.68, with a beta of 0.20.
Sarepta Therapeutics, Inc. does not currently pay a dividend.
55 Wall Street analyst ratings cover the stock: 31 Buy, 18 Hold and 6 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Sarepta Therapeutics, Inc. (SRPT) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 43.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 50.1% / 30% · Interest income / Revenue 1.86% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 43.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 44.3% / 33% · Receivables / Mkt Cap (36m) 18.6% / 49% · Interest income / Revenue 1.86% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 43.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 44.3% / 33.33% · Receivables / Mkt Cap (24m) 18.6% / 33.33% · Interest income / Revenue 1.86% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 26.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 25.3% / 33.33% · Receivables / Avg Assets (4Q) 14.9% / 33.33% · Interest income / Revenue 1.86% / 5% | Pass |
| FTSE | Debt / Total Assets 27.1% / 33.33% · (Cash+ST Inv) / Total Assets 27.8% / 33.33% · (Cash+Recv) / Total Assets 39.4% / 33.33% · Interest income / Revenue 1.86% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Sarepta Therapeutics, Inc. (SRPT) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
No. Sarepta Therapeutics, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 1.86% of each dividend: Sarepta Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.